YOUR SEARCH FOR Text 64 RESULTS
21 of Total
Events & Presentations | Incyte
… Presentations Date Title File Feb 10, 2026 Q4 2025 Financial and Corporate Update Presentation Q4 2025 Financial and Corporate Update Presentation …
22 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… with approval anticipated in the second half of 2025. In October, Opzelura was granted a Notice … by the end of 2024. A potential approval in 2025 could represent the first PD-(L)1 antibody …
23 of Total
Events & Presentations | Incyte
… Conference Feb 10, 2026 8:00 AM EST Q4/Year-End 2025 Incyte Corporation Earnings Conference Call … J. P. Morgan Healthcare Conference Dec 7, 2025 11:00 AM EST Incyte Investor Event - ASH …
24 of Total
Company Statements | Incyte.com
… these company statements. Incyte Celebrates the 2025 MPN Heroes ® , Extraordinary Individuals … Neoplasm (MPN) Community December 5, 2025 2025 lncyte Ingenuity Awards in GVHD™ …
25 of Total
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido
… or Refractory Follicular Lymphoma December 22, 2025 at 2:44 AM EST PDF Version TOKYO --(BUSINESS WIRE)--Dec. 22, 2025-- Incyte Biosciences Japan G.K. today …
26 of Total
Let’s Talk Anal Cancer | Incyte Stories
… December 11, 2025 Let’s Talk Anal Cancer More than 10,000 … . Accessed November 4, 2025. 2 Symer MM, Yeo HL. F1000Research. …
27 of Total
Incyte Leadership | Incyte.com
… Executive Officer Bill Meury joined Incyte in 2025 and is Chief Executive Officer (CEO) and a … Resources Officer Soni Basi joined Incyte in 2025 as Executive Vice President and Chief Human …
28 of Total
Incyte Involved: Unwavering Community Commitment | Incyte Stories
… May 22, 2025 Incyte Involved: Unwavering Community … more than 650 charities by Incyte employees In 2025, we are eager to expand our reach and …
29 of Total
Press Releases | Incyte
… in these press releases. Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 … Incyte Reports Fourth Quarter and Full Year 2025 Financial Results January 30, 2026 Incyte …
30 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Initial data for both studies is anticipated in 2025. MPN and GVHD Programs Indication and … A Phase 3 study is expected to initiate in 2025. Ruxolitinib cream in other indications: …